Staging Relationships and Outcome in Early Stage Testicular Cancer: A Report From the Testicular Cancer Intergroup Study

No AccessJournal of Urology1 Jun 1991Staging Relationships and Outcome in Early Stage Testicular Cancer: A Report From the Testicular Cancer Intergroup Study David G. Mcleod, Raymond B. Weiss, Donald M. Stablein, Franco M. Muggia, David F. Paulson, James H. Ellis, Joseph T. Spaulding, John P. Donohue, and For the Testicular Cancer Intergroup Study David G. McleodDavid G. Mcleod , Raymond B. WeissRaymond B. Weiss , Donald M. StableinDonald M. Stablein , Franco M. MuggiaFranco M. Muggia , David F. PaulsonDavid F. Paulson , James H. EllisJames H. Ellis , Joseph T. SpauldingJoseph T. Spaulding , John P. DonohueJohn P. Donohue , and For the Testicular Cancer Intergroup Study View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)38567-1AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The Testicular Cancer Intergroup Study entered surgically staged patients with nonseminomatous tumor and metastases limited to the regional lymph nodes into a previously reported cooperative trial of immediate versus delayed therapy for positive retroperitoneal node disease. Patients with negative nodes (stage I) were placed in an observation registry with specified treatment strategy upon relapse. Of 264 stage I cancer patients 27 (10.2%) had recurrence: 5 of these 27 patients died after recurrence of the testicular malignancies, while 4 other nontumor-related deaths have occurred. Pre-lymphadenectomy staging characteristics observed to predict significantly node positivity are the results of radiological examinations, presence of tumor invasion, vascular invasion and tumor histology. In a multiple logistic regression analysis with these variables, misclassification still occurs in more than a fourth of the patients. Future refinements in diagnosis may allow for better prediction of these patients at risk to have positive lymph nodes and ultimately recurrence. Presently, if assessment of nodal involvement is the objective, noninvasive procedures are not an adequate substitute for surgical staging with modified lymphadenectomy. © 1991 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByPOHAR K, RABBANI F, BOSL G, MOTZER R, BAJORIN D and SHEINFELD J (2018) Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the TestisJournal of Urology, VOL. 170, NO. 4 Part 1, (1155-1158), Online publication date: 1-Oct-2003.STUDER U, BURKHARD F and SONNTAG R (2018) RISK ADAPTED MANAGEMENT WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH RISK CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMORJournal of Urology, VOL. 163, NO. 6, (1785-1787), Online publication date: 1-Jun-2000.BOHLEN D, BORNER M, SONNTAG R, FEY M and STUDER U (2018) LONG-TERM RESULTS FOLLOWING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH CLINICAL STAGE I TESTICULAR NONSEMINOMATOUS MALIGNANT GERM CELL TUMORS WITH HIGH RISK FACTORSJournal of Urology, VOL. 161, NO. 4, (1148-1152), Online publication date: 1-Apr-1999.SOGANI P, PERROTTI M, HERR H, FAIR W, THALER H and BOSL G (2018) CLINICAL STAGE I TESTIS CANCER: LONG-TERM OUTCOME OF PATIENTS ON SURVEILLANCEJournal of Urology, VOL. 159, NO. 3, (855-858), Online publication date: 1-Mar-1998.Hoh C, Seltzer M, Franklin J, deKernion J, Phelps M and Belldegrun A (2018) POSITRON EMISSION TOMOGRAPHY IN UROLOGICAL ONCOLOGYJournal of Urology, VOL. 159, NO. 2, (347-356), Online publication date: 1-Feb-1998.Albers P, Ulbright T, Albers J, Miller G, Orazi A, Crabtree W, Baniel J, Reister T, Sidner R, Foster R and Donohue J (2018) Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell TumorsJournal of Urology, VOL. 155, NO. 2, (579-586), Online publication date: 1-Feb-1996.Moul J, Snow P, Fernandez E, Maher P and Sesterhenn I (2018) Neural Network Analysis of Quantitative Histological Factors to Predict Pathological Stage in Clinical Stage I Nonseminomatous Testicular CancerJournal of Urology, VOL. 153, NO. 5, (1674-1677), Online publication date: 1-May-1995.Swanson D (2018) Editorial: Low Stage Testis Cancer is Still Potentially LethalJournal of Urology, VOL. 154, NO. 4, (1376-1377), Online publication date: 1-Oct-1995.McCrystal M, Zwi L and Harvey V (2018) Case Reports: Late Seminomatous Relapse of a Mixed Germ Cell Tumor of the Testis on Intensive SurveillanceJournal of Urology, VOL. 153, NO. 3S, (1057-1059), Online publication date: 1-Mar-1995.Fernandez E, Sesterhenn I, McCarthy W, Mostofi F and Moul J (2018) Proliferating Cell Nuclear Antigen Expression to Predict Occult Disease in Clinical Stage I Nonseminomatous Testicular Germ Cell TumorsJournal of Urology, VOL. 152, NO. 4, (1133-1138), Online publication date: 1-Oct-1994.Lewis D, Sesterhenn I, McCarthy W and Moul J (2018) Immunohistochemical Expression of P53 Tumor Suppressor Gene Protein in Adult Germ Cell Testis Tumors: Clinical Correlation in Stage I DiseaseJournal of Urology, VOL. 152, NO. 2 Part 1, (418-423), Online publication date: 1-Aug-1994. Volume 145Issue 6June 1991Page: 1178-1182 Advertisement Copyright & Permissions© 1991 by The American Urological Association Education and Research, Inc.Keywordstesticular neoplasmstestisneoplasm stagingMetricsAuthor Information David G. Mcleod More articles by this author Raymond B. Weiss More articles by this author Donald M. Stablein More articles by this author Franco M. Muggia More articles by this author David F. Paulson More articles by this author James H. Ellis More articles by this author Joseph T. Spaulding More articles by this author John P. Donohue More articles by this author For the Testicular Cancer Intergroup Study More articles by this author Expand All Advertisement PDF DownloadLoading ...